The role of the subthalamic nucleus in L-DOPA induced dyskinesia in 6-hydroxydopamine lesioned rats

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Aristieta, Asier ^a   Azkona, Garikoitz ^b   Sagarduy, Ainhoa ^a   Miguelez, Cristina ^a   Ruiz Ortega, José Ángel ^a   Sanchez Pernaute, Rosario ^b   Ugedo, Luisa ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b Fundacion Inbiomed   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BUSPIRONE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR; IBOTENIC ACID; LEVODOPA; OXIDOPAMINE; PHOSPHOPROTEIN DARPP 32; TRANSCRIPTION FACTOR FOSB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CELL; BRAIN DAMAGE; BRAIN ELECTROPHYSIOLOGY; BRAIN FUNCTION; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFECT; DYSKINESIA; NEUROPATHOLOGY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSONISM; PROTEIN EXPRESSION; RAT; RECEPTOR UPREGULATION; SINGLE UNIT ACTIVITY; SUBTHALAMIC NUCLEUS; UPREGULATION;

ANIMALS; DYSKINESIA, DRUG-INDUCED; ELECTROPHYSIOLOGICAL PHENOMENA; LEVODOPA; NEOSTRIATUM; NEURONS; OXIDOPAMINE; PARKINSON DISEASE; RATS; RATS, SPRAGUE-DAWLEY; REGRESSION ANALYSIS; SUBTHALAMIC NUCLEUS;

ANIMALIA; PARKINSONIA; RATTUS;

EID: 84864649123     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0042652     Document Type: Article

References (90)

1. Kish SJ, Shannak K, Hornykiewicz O, ((1988)) Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med 318: 876-880.
2. Ahlskog JE, Muenter MD, ((2001)) Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 16: 448-458.
3. Wichmann T, Dostrovsky JO, ((2011)) Pathological basal ganglia activity in movement disorders. Neuroscience 198: 232-244.
4. Obeso JA, Olanow CW, Nutt JG, ((2000)) Levodopa motor complications in Parkinson's disease. Trends Neurosci 23: S2-S7.
5. Cesaro P, Damier P, Nguyen JP, Palfi S, Ollat H, ((2003)) La maladie de Parkinson.
6. Alexander GE, DeLong MR, Strick PL, ((1986)) Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 9: 357-381.
7. Obeso JA, Rodriguez-Oroz MC, Benitez-Temino B, Blesa FJ, Guridi J, et al. ((2008)) Functional organization of the basal ganglia: therapeutic implications for Parkinson's disease. Mov Disord 23 Suppl 3: S548-S559.
8. Bergman H, Wichmann T, Karmon B, DeLong MR, ((1994)) The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism. J Neurophysiol 72: 507-520.
9. Hassani OK, Mouroux M, Feger J, ((1996)) Increased subthalamic neuronal activity after nigral dopaminergic lesion independent of disinhibition via the globus pallidus. Neuroscience 72: 105-115.
10. Vila M, Perier C, Feger J, Yelnik J, Faucheux B, et al. ((2000)) Evolution of changes in neuronal activity in the subthalamic nucleus of rats with unilateral lesion of the substantia nigra assessed by metabolic and electrophysiological measurements. Eur J Neurosci 12: 337-344.
11. Magill PJ, Bolam JP, Bevan MD, ((2001)) Dopamine regulates the impact of the cerebral cortex on the subthalamic nucleus-globus pallidus network. Neuroscience 106: 313-330.
12. Breit S, Bouali-Benazzouz R, Popa RC, Gasser T, Benabid AL, et al. ((2007)) Effects of 6-hydroxydopamine-induced severe or partial lesion of the nigrostriatal pathway on the neuronal activity of pallido-subthalamic network in the rat. Exp Neurol 205: 36-47.
13. Russmann H, Ghika J, Combrement P, Villemure JG, Bogousslavsky J, et al. ((2004)) L-dopa-induced dyskinesia improvement after STN-DBS depends upon medication reduction. Neurology 63: 153-155.
14. Apetauerova D, Ryan RK, Ro SI, Arle J, Shils J, et al. ((2006)) End of day dyskinesia in advanced Parkinson's disease can be eliminated by bilateral subthalamic nucleus or globus pallidus deep brain stimulation. Mov Disord 21: 1277-1279.
15. Guridi J, Obeso JA, Rodriguez-Oroz MC, Lozano AA, Manrique M, ((2008)) L-dopa-induced dyskinesia and stereotactic surgery for Parkinson's disease. Neurosurgery 62: 311-323.
16. Nishikawa Y, Kobayashi K, Oshima H, Fukaya C, Yamamoto T, et al. ((2010)) Direct relief of levodopa-induced dyskinesia by stimulation in the area above the subthalamic nucleus in a patient with Parkinson's disease-case report. Neurol Med Chir (Tokyo) 50: 257-259.
17. Katayama Y, Oshima H, Kano T, Kobayashi K, Fukaya C, et al. ((2006)) Direct effect of subthalamic nucleus stimulation on levodopa-induced peak-dose dyskinesia in patients with Parkinson's disease. Stereotact Funct Neurosurg 84: 176-179.
18. Zheng Z, Li Y, Li J, Zhang Y, Zhang X, et al. ((2010)) Stimulation-induced dyskinesia in the early stage after subthalamic deep brain stimulation. Stereotact Funct Neurosurg 88: 29-34.
19. Paxinos G, Watson C (1997) The rat brain in stereotaxic coordinates. (3rd edn). Orlando: Academic Press.
20. Miguelez C, Aristieta A, Cenci MA, Ugedo L, ((2011)) The locus coeruleus is directly implicated in L-DOPA-induced dyskinesia in parkinsonian rats: an electrophysiological and behavioural study. PLoS One 6: e24679.
21. Cenci MA, Lundblad M, ((2007)) Ratings of L-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson's disease in rats and mice. Curr Protoc Neurosci Chapter 9: Unit.
22. Carlsson T, Winkler C, Burger C, Muzyczka N, Mandel RJ, et al. ((2005)) Reversal of dyskinesias in an animal model of Parkinson's disease by continuous L-DOPA delivery using rAAV vectors. Brain 128: 559-569.
23. Lindgren HS, Andersson DR, Lagerkvist S, Nissbrandt H, Cenci MA, ((2010)) L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia. J Neurochem 112: 1465-1476.
24. Morera-Herreras T, Ruiz-Ortega JA, Ugedo L, ((2010)) Two opposite effects of Delta(9)-tetrahydrocannabinol on subthalamic nucleus neuron activity: involvement of GABAergic and glutamatergic neurotransmission. Synapse 64: 20-29.
25. Hollerman JR, Grace AA, ((1992)) Subthalamic nucleus cell firing in the 6-OHDA-treated rat: basal activity and response to haloperidol. Brain Res 590: 291-299.
26. Kaneoke Y, Vitek JL, ((1996)) Burst and oscillation as disparate neuronal properties. J Neurosci Methods 68: 211-223.
27. Morera-Herreras T, Ruiz-Ortega JA, Gomez-Urquijo S, Ugedo L, ((2008)) Involvement of subthalamic nucleus in the stimulatory effect of Delta(9)-tetrahydrocannabinol on dopaminergic neurons. Neuroscience 151: 817-823.
28. Azkona G, Mador-Arjona A, Obradors-Tarrago C, Varea E, Arque G, et al. ((2010)) Characterization of a mouse model overexpressing beta-site APP-cleaving enzyme 2 reveals a new role for BACE2. Genes Brain Behav 9: 160-172.
29. Dekundy A, Lundblad M, Danysz W, Cenci MA, ((2007)) Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model. Behav Brain Res 179: 76-89.
30. Eskow KL, Gupta V, Alam S, Park JY, Bishop C, ((2007)) The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy. Pharmacol Biochem Behav 87: 306-314.
31. Kobylecki C, Hill MP, Crossman AR, Ravenscroft P, ((2011)) Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease. Mov Disord 26: 2354-2363.
32. Lundblad M, Andersson M, Winkler C, Kirik D, Wierup N, et al. ((2002)) Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur J Neurosci 15: 120-132.
33. Lundblad M, Vaudano E, Cenci MA, ((2003)) Cellular and behavioural effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of l-DOPA-induced dyskinesia. J Neurochem 84: 1398-1410.
34. Marin C, Jimenez A, Bonastre M, Vila M, Agid Y, et al. ((2001)) LY293558, an AMPA glutamate receptor antagonist, prevents and reverses levodopa-induced motor alterations in Parkinsonian rats. Synapse 42: 40-47.
35. Munoz A, Li Q, Gardoni F, Marcello E, Qin C, Carlsson T, et al. ((2008)) Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. Brain 131: 3380-3394.
36. Cenci MA, Lee CS, Bjorklund A, ((1998)) L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur J Neurosci 10: 2694-2706.
37. Dekundy A, Lundblad M, Danysz W, Cenci MA, ((2007)) Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model. Behav Brain Res 179: 76-89.
38. Andersson M, Hilbertson A, Cenci MA, ((1999)) Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease. Neurobiol Dis 6: 461-474.
39. Benazzouz A, Gross C, Feger J, Boraud T, Bioulac B, ((1993)) Reversal of rigidity and improvement in motor performance by subthalamic high-frequency stimulation in MPTP-treated monkeys. Eur J Neurosci 5: 382-389.
40. Bergman H, Wichmann T, DeLong MR, ((1990)) Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 249: 1436-1438.
41. Gill SS, Heywood P, ((1997)) Bilateral dorsolateral subthalamotomy for advanced Parkinson's disease. Lancet 350: 1224.
42. Limousin P, Pollak P, Benazzouz A, Hoffmann D, Le Bas JF, et al. ((1995)) Effect of parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. Lancet 345: 91-95.
43. Burbaud P, Gross C, Benazzouz A, Coussemacq M, Bioulac B, ((1995)) Reduction of apomorphine-induced rotational behaviour by subthalamic lesion in 6-OHDA lesioned rats is associated with a normalization of firing rate and discharge pattern of pars reticulata neurons. Exp Brain Res 105: 48-58.
44. Piallat B, Benazzouz A, Benabid AL, ((1999)) Neuroprotective effect of chronic inactivation of the subthalamic nucleus in a rat model of Parkinson's disease. J Neural Transm Suppl 55: 71-77.
45. Ni ZG, Bouali-Benazzouz R, Gao DM, Benabid AL, Benazzouz A, ((2001)) Time-course of changes in firing rates and firing patterns of subthalamic nucleus neuronal activity after 6-OHDA-induced dopamine depletion in rats. Brain Res 899: 142-147.
46. Morera-Herreras T, Ruiz-Ortega JA, Linazasoro G, Ugedo L, ((2011)) Nigrostriatal denervation changes the effect of cannabinoids on subthalamic neuronal activity in rats. Psychopharmacology (Berl) 214: 379-389.
47. Boyson SJ, McGonigle P, Molinoff PB, ((1986)) Quantitative autoradiographic localization of the D1 and D2 subtypes of dopamine receptors in rat brain. J Neurosci 6: 3177-3188.
48. Bouthenet ML, Martres MP, Sales N, Schwartz JC, ((1987)) A detailed mapping of dopamine D-2 receptors in rat central nervous system by autoradiography with [125I]iodosulpride. Neuroscience 20: 117-155.
49. Johnson AE, Coirini H, Kallstrom L, Wiesel FA, ((1994)) Characterization of dopamine receptor binding sites in the subthalamic nucleus. Neuroreport 5: 1836-1838.
50. Flores G, Liang JJ, Sierra A, Martinez-Fong D, Quirion R, et al. ((1999)) Expression of dopamine receptors in the subthalamic nucleus of the rat: characterization using reverse transcriptase-polymerase chain reaction and autoradiography. Neuroscience 91: 549-556.
51. Brown LL, Markman MH, Wolfson LI, Dvorkin B, Warner C, et al. ((1979)) A direct role of dopamine in the rat subthalamic nucleus and an adjacent intrapeduncular area. Science 206: 1416-1418.
52. Mitchell IJ, Clarke CE, Boyce S, Robertson RG, Peggs D, et al. ((1989)) Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neuroscience 32: 213-226.
53. Canteras NS, Shammah-Lagnado SJ, Silva BA, Ricardo JA, ((1990)) Afferent connections of the subthalamic nucleus: a combined retrograde and anterograde horseradish peroxidase study in the rat. Brain Res 513: 43-59.
54. Ni Z, Gao D, Bouali-Benazzouz R, Benabid AL, Benazzouz A, ((2001)) Effect of microiontophoretic application of dopamine on subthalamic nucleus neuronal activity in normal rats and in rats with unilateral lesion of the nigrostriatal pathway. Eur J Neurosci 14: 373-381.
55. Kreiss DS, Mastropietro CW, Rawji SS, Walters JR, ((1997)) The response of subthalamic nucleus neurons to dopamine receptor stimulation in a rodent model of Parkinson's disease. J Neurosci 17: 6807-6819.
56. Zhu Z, Bartol M, Shen K, Johnson SW, ((2002)) Excitatory effects of dopamine on subthalamic nucleus neurons: in vitro study of rats pretreated with 6-hydroxydopamine and levodopa. Brain Res 945: 31-40.
57. Gilmour TP, Lieu CA, Nolt MJ, Piallat B, Deogaonkar M, et al. ((2011)) The effects of chronic levodopa treatments on the neuronal firing properties of the subthalamic nucleus and substantia nigra reticulata in hemiparkinsonian rhesus monkeys. Exp Neurol 228: 53-58.
58. Lozano AM, Lang AE, Levy R, Hutchison W, Dostrovsky J, ((2000)) Neuronal recordings in Parkinson's disease patients with dyskinesias induced by apomorphine. Ann Neurol 47: S141-S146.
59. Murer MG, Moratalla R, ((2011)) Striatal Signaling in L-DOPA-Induced Dyskinesia: Common Mechanisms with Drug Abuse and Long Term Memory Involving D1 Dopamine Receptor Stimulation. Front Neuroanat 5: 51.
60. Lopez de MR, Sanchez-Pernaute R, ((2010)) Regulation of corticostriatal synaptic plasticity by G protein-coupled receptors. CNS Neurol Disord Drug Targets 9: 601-615.
61. Sanchez-Pernaute R, Jenkins BG, Choi JK, Iris Chen YC, Isacson O, ((2007)) In vivo evidence of D3 dopamine receptor sensitization in parkinsonian primates and rodents with l-DOPA-induced dyskinesias. Neurobiol Dis 27: 220-227.
62. Kumar R, Riddle LR, Griffin SA, Chu W, Vangveravong S, et al. ((2009)) Evaluation of D2 and D3 dopamine receptor selective compounds on L-dopa-dependent abnormal involuntary movements in rats. Neuropharmacology 56: 956-969.
63. Visanji NP, Fox SH, Johnston T, Reyes G, Millan MJ, et al. ((2009)) Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease. Neurobiol Dis 35: 184-192.
64. Sanchez-Pernaute R, Wang JQ, Kuruppu D, Cao L, Tueckmantel W, et al. ((2008)) Enhanced binding of metabotropic glutamate receptor type 5 (mGluR5) PET tracers in the brain of parkinsonian primates. Neuroimage 42: 248-251.
65. Breysse N, Baunez C, Spooren W, Gasparini F, Amalric M, ((2002)) Chronic but not acute treatment with a metabotropic glutamate 5 receptor antagonist reverses the akinetic deficits in a rat model of parkinsonism. J Neurosci 22: 5669-5678.
66. Battaglia G, Busceti CL, Molinaro G, Biagioni F, Storto M, et al. ((2004)) Endogenous activation of mGlu5 metabotropic glutamate receptors contributes to the development of nigro-striatal damage induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. J Neurosci 24: 828-835.
67. Aguirre JA, Kehr J, Yoshitake T, Liu FL, Rivera A, et al. ((2005)) Protection but maintained dysfunction of nigral dopaminergic nerve cell bodies and striatal dopaminergic terminals in MPTP-lesioned mice after acute treatment with the mGluR5 antagonist MPEP. Brain Res 1033: 216-220.
68. Armentero MT, Fancellu R, Nappi G, Bramanti P, Blandini F, ((2006)) Prolonged blockade of NMDA or mGluR5 glutamate receptors reduces nigrostriatal degeneration while inducing selective metabolic changes in the basal ganglia circuitry in a rodent model of Parkinson's disease. Neurobiol Dis 22: 1-9.
69. Vernon AC, Zbarsky V, Datla KP, Croucher MJ, Dexter DT, ((2007)) Subtype selective antagonism of substantia nigra pars compacta Group I metabotropic glutamate receptors protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivo. J Neurochem 103: 1075-1091.
70. Mela F, Marti M, Dekundy A, Danysz W, Morari M, et al. ((2007)) Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease. J Neurochem 101: 483-497.
71. Levandis G, Bazzini E, Armentero MT, Nappi G, Blandini F, ((2008)) Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-DOPA-induced dyskinesias in a rodent model of Parkinson's disease. Neurobiol Dis 29: 161-168.
72. Rylander D, Recchia A, Mela F, Dekundy A, Danysz W, et al. ((2009)) Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling. J Pharmacol Exp Ther 330: 227-235.
73. Johnston TH, Fox SH, McIldowie MJ, Piggott MJ, Brotchie JM, ((2010)) Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J Pharmacol Exp Ther 333: 865-873.
74. Morin N, Gregoire L, Gomez-Mancilla B, Gasparini F, Di PT, ((2010)) Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys. Neuropharmacology 58: 981-986.
75. Rylander D, Parent M, O'Sullivan SS, Dovero S, Lees AJ, et al. ((2010)) Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia. Ann Neurol 68: 619-628.
76. Kita H, Kitai ST, ((1987)) Efferent projections of the subthalamic nucleus in the rat: light and electron microscopic analysis with the PHA-L method. J Comp Neurol 260: 435-452.
77. Rinvik E, Ottersen OP, ((1993)) Terminals of subthalamonigral fibres are enriched with glutamate-like immunoreactivity: an electron microscopic, immunogold analysis in the cat. J Chem Neuroanat 6: 19-30.
78. Shimo Y, Wichmann T, ((2009)) Neuronal activity in the subthalamic nucleus modulates the release of dopamine in the monkey striatum. Eur J Neurosci 29: 104-113.
79. Wallace BA, Ashkan K, Heise CE, Foote KD, Torres N, et al. ((2007)) Survival of midbrain dopaminergic cells after lesion or deep brain stimulation of the subthalamic nucleus in MPTP-treated monkeys. Brain 130: 2129-2145.
80. Lacombe E, Carcenac C, Boulet S, Feuerstein C, Bertrand A, et al. ((2007)) High-frequency stimulation of the subthalamic nucleus prolongs the increase in striatal dopamine induced by acute l-3,4-dihydroxyphenylalanine in dopaminergic denervated rats. Eur J Neurosci 26: 1670-1680.
81. Oueslati A, Sgambato-Faure V, Melon C, Kachidian P, Gubellini P, et al. ((2007)) High-frequency stimulation of the subthalamic nucleus potentiates L-DOPA-induced neurochemical changes in the striatum in a rat model of Parkinson's disease. J Neurosci 27: 2377-2386.
82. Nimura T, Yamaguchi K, Ando T, Shibuya S, Oikawa T, et al. ((2005)) Attenuation of fluctuating striatal synaptic dopamine levels in patients with Parkinson disease in response to subthalamic nucleus stimulation: a positron emission tomography study. J Neurosurg 103: 968-973.
83. Hilker R, Voges J, Thiel A, Ghaemi M, Herholz K, et al. ((2002)) Deep brain stimulation of the subthalamic nucleus versus levodopa challenge in Parkinson's disease: measuring the on- and off-conditions with FDG-PET. J Neural Transm 109: 1257-1264.
84. Strafella AP, Sadikot AF, Dagher A, ((2003)) Subthalamic deep brain stimulation does not induce striatal dopamine release in Parkinson's disease. Neuroreport 14: 1287-1289.
85. Thobois S, Fraix V, Savasta M, Costes N, Pollak P, et al. ((2003)) Chronic subthalamic nucleus stimulation and striatal D2 dopamine receptors in Parkinson's disease-A [(11)C]-raclopride PET study. J Neurol 250: 1219-1223.
86. Bonifati V, Fabrizio E, Cipriani R, Vanacore N, Meco G, ((1994)) Buspirone in levodopa-induced dyskinesias. Clin Neuropharmacol 17: 73-82.
87. Gerlach M, Beck J, Riederer P, van den BM, ((2011)) Flibanserin attenuates L:-DOPA-sensitized contraversive circling in the unilaterally 6-hydroxydopamine-lesioned rat model of Parkinson's disease. J Neural Transm 118: 1727-1732.
88. Shin E, Garcia J, Winkler C, Bjorklund A, Carta M, ((2012)) Serotonergic and dopaminergic mechanisms in graftinduced dyskinesia in a rat model of Parkinson's disease. Neurobiol Dis 4: 393-406.
89. Capus L, Melatini A, Zorzon M, Torre P, Carraro N, et al. ((2001)) Chronic bilateral electrical stimulation of the subthalamic nucleus for the treatment of advanced Parkinson's disease. Neurol Sci 22: 57-58.
90. Rodriguez-Oroz MC, Obeso JA, Lang AE, Houeto JL, Pollak P, et al. ((2005)) Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up. Brain 128: 2240-2249.